Otros idiomas Galmed Pharmaceuticals Ltd.

Acciones

GLMD

IL0011313900

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
0,352 ^USD	-7,12 %		-2,60 %	-22,64 %

04/04	Galmed Pharmaceuticals Ltd. Resultados del ejercicio finalizado el 31 de diciembre de 2023	CI
15/03	Galmed Pharmaceuticals Ltd. Anuncia la Concesión de una Nueva Patente para la Combinación de Aramchol con Resmetirom (MGL-3196, REZDIFFRA) para el Tratamiento de la Nash y la Fibrosis Hepática	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/04
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	15/03
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis	15/03
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K	22/11
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	22/11
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	21/11
Sector Update: Health Care	21/11
Top Midday Decliners	21/11
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study	20/11
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study	20/11
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis	26/09/23
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	25/09/23
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	22/09/23
Galmed Pharmaceuticals: Q2 Earnings Snapshot	10/08/23
Galmed Pharmaceuticals : 16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K	09/08/23
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Galmed Pharmaceuticals : Securities Purchase Agreement - Form 6-K	18/07/23
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering	17/07/23
Top Midday Decliners	14/07/23
Galmed Pharmaceuticals Prices $7 Million Securities Offering; Shares Slump	14/07/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Galmed Pharmaceuticals Ltd.

Acciones

GLMD

IL0011313900

Otros idiomas

Filtros